Treatment of Medication-Related Osteonecrosis of the Jaws without Segmental Resections: A Case Series

Am J Case Rep. 2024 Feb 26:25:e942980. doi: 10.12659/AJCR.942980.

Abstract

BACKGROUND Medication-related osteonecrosis of the jaw (MRONJ) is a rare but serious reaction to anti-resorptive drugs (ARDs) in patients treated for osteoporosis and conditions related to cancer. Treatment for MRONJ consists of the use of non-operative therapies according to the evolution of the disease, which consist of the use of antimicrobial mouthwashes, systemic antibiotics, and operative therapies, such as debridement of necrotic bone, marginal or segmental resection, and bone reconstruction of the jaws in more advanced stages of the disease. CASE REPORT This is a case series of 11 female patients treated for MRONJ, with a mean age of 76.5 years. Patients with malignant diseases of the jaws or those undergoing head and neck radiotherapy were excluded. Nine patients were medicated for osteoporosis with oral bisphosphonates and denosumab, and 2 patients used zoledronate to treat metastatic breast cancer. MRONJ prevailed in the mandible, most patients were classified as stage 2, and the most frequent triggers were tooth extraction and prosthetic trauma. All patients initially underwent non-operative therapies and were operated according to MRONJ stage, but none required segmental resection. Adjuvant treatments were used in 5 patients, and mean treatment and follow-up periods were 5 and 18.3 months, respectively. There was complete resolution of disease in all patients, with only 1 relapse. CONCLUSIONS This case series suggests that it is possible to treat MRONJ with conservative therapies in the early stages of the disease and minimally invasive surgeries in more advanced stages of the disease, thus avoiding segmental jaw resections.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Bisphosphonate-Associated Osteonecrosis of the Jaw* / etiology
  • Bisphosphonate-Associated Osteonecrosis of the Jaw* / surgery
  • Bone Density Conservation Agents* / adverse effects
  • Diphosphonates / adverse effects
  • Female
  • Humans
  • Jaw
  • Neoplasm Recurrence, Local / complications
  • Osteoporosis* / chemically induced
  • Osteoporosis* / complications
  • Osteoporosis* / drug therapy

Substances

  • Diphosphonates
  • Bone Density Conservation Agents